Cancer Genetics, Inc. Will Open Precision Medicine

RUTHERFORD, N.J., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its vice president of R&D, Jane Houldsworth, Ph.D., will provide the opening keynote presentation for the "Realizing the Potential of Precision Medicine" conference on October 9, 2013 at 1:00 pm ET.

"The use of genetic information to improve diagnosis, treatment and patient outcomes is the very foundation of precision medicine," stated Panna Sharma, CEO of CGI. "This conference brings together key industry thought leaders to provide attendees with insights on how to apply precision medicine in the clinical setting. Participating companies include major players in genetics, such as Illumina and Luminex. Other participants include Weill Cornell Medical College, New-York Presbyterian Hospital and other key institutions that serve the needs of oncology patients. For CGI to have the honor of opening this conference is a testament to our leadership position in the rapidly evolving field of precision medicine."

Dr. Houldsworth's keynote "From Vision to Reality, the Cancer Genetics Complete Experience," will use CGI's Complete Programs™ as a case study to strategize the introduction and successful licensure of molecular and biomarker based diagnostic testing. Her keynote will also address preparation for constant upgrading and expansion to include novel findings and methodological advances.

Dr. Houldsworth has over 20 years of experience in translational research and has published more than 50 peer-reviewed papers and 15 chapters. Since her joining CGI in 2007, Dr. Houldsworth has successfully led the clinical validations and licensures of CGI's proprietary products including MatBA® and UroGenRA™.

The conference, "Realizing the Potential of Precision Medicine," will take place at the AMA Conference Center in New York City, October 9 to October 11, 2013. Registration can be done at http://goo.gl/aHOxff . The conference is suited for executives and health care professionals representing academic medical centers, community hospitals, and hospital and health networks, and the event should provide networking and deal-making opportunities.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com .

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107